Stiller Charles A, Botta Laura, Brewster David H, Ho Vincent K Y, Frezza Anna Maria, Whelan Jeremy, Casali Paolo G, Trama Annalisa, Gatta Gemma
National Cancer Registration and Analysis Service, Public Health England, 4150 Chancellor Court, Oxford OX4 2GX, UK.
Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.
Cancer Epidemiol. 2018 Oct;56:146-153. doi: 10.1016/j.canep.2018.08.010. Epub 2018 Sep 1.
Five-year relative survival (RS) of adults with bone and soft-tissue cancers in Europe was still <60% by 1995-1999. There was large geographical survival variability, mainly for bone tumours, and survival decreased with increasing age at diagnosis.
Data from 87 population-based cancer registries in 29 countries, extracted from the EUROCARE-5 database, were used to provide updated estimates of survival and describe trends in survival of adults with cancers of these sites across Europe. We calculated 5-year RS for patients diagnosed in 2000-2007. We estimated 5-year RS by the period approach to assess changes in survival between 1999-2001, 2002-2004 and 2005-2007, and provide reliable predictions for recently diagnosed patients.
Five-year RS was 60% for adults diagnosed with soft-tissue cancer in 2000-2007 and 53% for those with bone cancer. RS declined with increasing age at diagnosis, especially for bone cancer. Survival from bone cancer varied widely between European regions, from 63 to 62% in Northern and Central Europe to 39% in Eastern Europe. Inter-regional variation was much less for soft-tissue cancer. For both site groupings, there was little evidence of change in five-year RS up to 2002-2004, followed by increases of 3-4% during 2005-2007.
Outcomes for adults with bone and soft-tissue cancer in Europe began to improve around 2005; new therapeutic developments are expected to result in further progress. Survival improvements already achieved must be brought more fully to elderly patients and those in Eastern Europe. European Reference Networks on rare cancers will have a vital role in future progress.
到1995 - 1999年，欧洲成人骨癌和软组织癌患者的五年相对生存率（RS）仍低于60%。存在较大的地理生存差异，主要体现在骨肿瘤方面，且生存率随诊断时年龄的增加而降低。
从EUROCARE - 5数据库中提取的29个国家87个基于人群的癌症登记处的数据，用于提供生存情况的最新估计，并描述欧洲这些部位癌症成人患者的生存趋势。我们计算了2000 - 2007年诊断患者的五年RS。我们采用时期法估计五年RS，以评估1999 - 2001年、2002 - 2004年和2005 - 2007年期间的生存变化，并为近期诊断的患者提供可靠预测。
2000 - 2007年诊断为软组织癌的成人患者五年RS为60%，骨癌患者为53%。RS随诊断时年龄的增加而下降，尤其是骨癌。欧洲各地区骨癌的生存率差异很大，北欧和中欧为63%至62%，东欧为39%。软组织癌的区域间差异要小得多。对于这两个部位的癌症，在2002 - 2004年之前几乎没有证据表明五年RS有变化，随后在2005 - 2007年期间增加了3 - 4%。
欧洲成人骨癌和软组织癌患者的预后在2005年左右开始改善；新的治疗进展有望带来进一步的进步。必须让老年患者和东欧患者更充分地受益于已取得的生存改善。欧洲罕见癌症参考网络将在未来的进展中发挥至关重要的作用。
